{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:44:59Z","timestamp":1788875099403,"version":"build-2803163510"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jconrel.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T13:45:34Z","timestamp":1715780734000},"page":"707-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials"],"prefix":"10.1016","volume":"370","author":[{"given":"RamaRao","family":"Malla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mundla","family":"Srilatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda","family":"Muppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Farran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virander Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.05.020_bb0005","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.annonc.2021.08.2153","article-title":"Therapeutic cancer vaccines revamping: technology advancements and pitfalls","volume":"32","author":"Antonelli","year":"2021","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020085","article-title":"Cancer vaccines: antigen selection strategy","volume":"9","author":"Zhao","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tranon.2019.02.008","article-title":"Cancer-testis antigen peptide vaccine for Cancer immunotherapy: Progress and prospects","volume":"12","author":"Wei","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0020","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5519","article-title":"Cancer testis antigen subfamilies: attractive targets for therapeutic vaccine (review)","volume":"62","author":"Ren","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00286-10","article-title":"Translating tumor antigens into cancer vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153875","article-title":"Cancer-testis antigens in triple-negative breast Cancer: role and potential utility in clinical practice","volume":"13","author":"Lam","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The role of Neoantigens in naturally occurring and therapeutically induced immune responses to Cancer","volume":"130","author":"Ward","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164245","article-title":"Identification and targeting of mutant peptide Neoantigens in Cancer immunotherapy","volume":"13","author":"Verdon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2019.10.023","article-title":"Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer","volume":"72","author":"Benvenuto","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0070","first-page":"215","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines, nature reviews","volume":"18","author":"Blass","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0075","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer, Biochimica et biophysica acta","volume":"1876","author":"Zhu","year":"2021","journal-title":"Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007336","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Brito Baleeiro","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10549-021-06459-2","article-title":"Breast cancer vaccines for treatment and prevention","volume":"191","author":"Disis","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0090","article-title":"Impact of Neoantigen expression and T-cell activation on breast Cancer survival","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0100","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1038\/s41598-019-48064-w","article-title":"Cancer testis antigen promotes triple negative breast Cancer metastasis and is traceable in the circulating extracellular vesicles","volume":"9","author":"Kannan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0105","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002115","article-title":"MUC1-C integrates activation of the IFN-\u03b3 pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer","volume":"9","author":"Yamashita","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C induces PD-L1 and immune evasion in triple-negative breast Cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","article-title":"The MAGE protein family and cancer","volume":"37","author":"Weon","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2010.10.021","article-title":"Melanoma-associated antigen genes - an update","volume":"302","author":"Sang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0130","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s12032-012-0172-5","article-title":"High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer","volume":"29","author":"Badovinac \u010crnjevi\u0107","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0135","first-page":"1758","article-title":"CTLA-4 blockade combined with 5-aza-2\u2032-deoxycytidine enhances the killing effect of MAGE-A family common antigen peptide-specific cytotoxic T cells on breast cancer","volume":"44","author":"Li","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of Cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5cdf6105-2a52-497a-86b3-db8f4a4e439c","article-title":"NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer","volume":"7","author":"Ademuyiwa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000439535","article-title":"Expression of NY-ESO-1 in triple-negative breast Cancer is associated with tumor-infiltrating lymphocytes and a good prognosis","volume":"89","author":"Lee","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154299","article-title":"The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas","volume":"241","author":"See","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0160","article-title":"Exploring the role of CD151 in the tumor immune microenvironment: therapeutic and clinical perspectives, Biochimica et biophysica acta","volume":"1878","author":"Malla","year":"2023","journal-title":"Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/BIC.S21847","article-title":"CD151-a striking marker for Cancer therapy","volume":"7","author":"Kumari","year":"2015","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0175","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1042\/BST0390506","article-title":"Tetraspanins in cellular immunity","volume":"39","author":"Jones","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ebiom.2019.10.025","article-title":"Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis","volume":"49","author":"Lin","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0185","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/imt-2017-0179","article-title":"Cancer testis antigens as immunogenic and oncogenic targets in breast cancer","volume":"10","author":"Mahmoud","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0190","doi-asserted-by":"crossref","first-page":"25356","DOI":"10.18632\/oncotarget.4516","article-title":"CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer","volume":"6","author":"Paret","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0195","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0200","article-title":"Selecting target antigens for Cancer vaccine development","volume":"8","author":"Buonaguro","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0205","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-13-144","article-title":"Derepression of Cancer\/testis antigens in cancer is associated with distinct patterns of DNA Hypomethylation","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0210","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57679","article-title":"The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGF\u03b2 signaling in triple-negative breast cancer","volume":"9","author":"Gibbs","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0215","doi-asserted-by":"crossref","first-page":"1164514","DOI":"10.3389\/fimmu.2023.1164514","article-title":"Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer","volume":"14","author":"Lian","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0220","doi-asserted-by":"crossref","first-page":"52","DOI":"10.17305\/bjbms.2018.3399","article-title":"Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR\/PI3K\/Akt pathway","volume":"19","author":"Han","year":"2019","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0225","article-title":"Genomic instability and Cancer","volume":"5","author":"Yao","year":"2014","journal-title":"J. Carcinog. Mutagen"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314937","article-title":"Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast Cancer","volume":"23","author":"Kudelova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.14720","article-title":"Neoantigen prediction in human breast cancer using RNA sequencing data","volume":"112","author":"Hashimoto","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41598-018-36319-x","article-title":"Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0245","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/ijc.33463","article-title":"Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation","volume":"148","author":"Pan","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0250","first-page":"932","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 Neoantigens in human solid tumors, Cancer","volume":"10","author":"Kim","year":"2022","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0255","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common <i>TP53<\/i> mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0260","article-title":"A comprehensive survey of genomic mutations in breast Cancer reveals recurrent Neoantigens as potential therapeutic targets","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.985886","article-title":"Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer","volume":"13","author":"Aparicio","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0270","doi-asserted-by":"crossref","first-page":"63963","DOI":"10.18632\/oncotarget.19246","article-title":"Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0275","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0280","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1038\/s41467-021-27620-x","article-title":"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response","volume":"12","author":"Yen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10101597","article-title":"Identification of shared Neoantigens in BRCA1-related breast Cancer","volume":"10","author":"Ruangapirom","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0290","first-page":"516","article-title":"Breast Cancer Neoantigens can induce CD8(+) T-cell responses and antitumor immunity, Cancer","volume":"5","author":"Zhang","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0295","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fbioe.2020.00702","article-title":"Characterization of Neoantigen load subgroups in gynecologic and breast cancers","volume":"8","author":"Zhu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0300","article-title":"Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer","author":"Zhang","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0305","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.annonc.2020.08.209","article-title":"88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo) adjuvant patients with triple negative breast cancer","volume":"31","author":"Schmidt","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0310","article-title":"Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0315","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0320","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.it.2021.02.009","article-title":"Uncloaking breast tumor Neoantigens with radiation","volume":"42","author":"Newman","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109444","article-title":"Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1\/PD-L1 immune checkpoint blocking","volume":"113","author":"He","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0330","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002549","article-title":"Protein citrullination as a source of cancer neoantigens","volume":"9","author":"Katayama","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.818693","article-title":"Comprehensive analysis of the Immunogenomics of triple-negative breast Cancer brain metastases from LCCC1419","volume":"12","author":"Routh","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0345","article-title":"Preclinical and clinical development of neoantigen vaccines, annals of oncology\u202f: official journal of the European society for","volume":"28","author":"Li","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0350","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.7150\/thno.60211","article-title":"Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response","volume":"11","author":"Zhao","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0355","first-page":"1058","article-title":"Extraction of human organ-specific cancer neoantigens from cancer cells and plasma membranes with 1-butanol","volume":"47","author":"Labateya","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00005-021-00615-8","article-title":"Neoantigen Cancer vaccines: real opportunity or another illusion?","volume":"69","author":"Manoutcharian","year":"2021","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030392","article-title":"Current trends in Neoantigen-based Cancer vaccines","volume":"16","author":"Ho","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0370","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-981-10-6020-5_15","article-title":"Progress in vaccine therapies for breast Cancer","volume":"1026","author":"Li","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0375","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived Neoantigens for Cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194883","article-title":"Immunomodulating therapies in breast Cancer-from prognosis to clinical practice","volume":"13","author":"Schmidt","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0385","doi-asserted-by":"crossref","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0390","doi-asserted-by":"crossref","first-page":"1246682","DOI":"10.3389\/fimmu.2023.1246682","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0395","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.vaccine.2023.02.048","article-title":"In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer","volume":"41","author":"Lu","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0400","doi-asserted-by":"crossref","first-page":"1685300","DOI":"10.1080\/2162402X.2019.1685300","article-title":"A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer","volume":"9","author":"DeVette","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0405","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s00262-021-02919-2","article-title":"Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens","volume":"70","author":"Gao","year":"2021","journal-title":"Cancer Immunol., Immunotherap. : CII"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-021-00872-4","article-title":"Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation","volume":"13","author":"Li","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0415","first-page":"2130","article-title":"NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells, clinical cancer research\u202f: an official journal of the American association for","volume":"15","author":"Gnjatic","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.15171\/bi.2019.06","article-title":"In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens","volume":"9","author":"Parvizpour","year":"2019","journal-title":"BioImpacts : BI"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0425","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond just peptide antigens: the complex world of peptide-based Cancer vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0435","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsabm.1c01238","article-title":"Peptides for Vaccine Development","volume":"5","author":"Hamley","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0440","doi-asserted-by":"crossref","first-page":"9749363","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for Cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10111882","article-title":"Adjuvant treatment for breast Cancer patients using individualized Neoantigen peptide vaccination-a retrospective observation","volume":"10","author":"Zelba","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002927","article-title":"Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma","volume":"10","author":"Mohsen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0455","first-page":"123","article-title":"A novel engineered AAV-based Neoantigen vaccine in combination with radiotherapy eradicates tumors, Cancer","volume":"11","author":"Huang","year":"2023","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymthe.2023.10.024","article-title":"mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer","volume":"32","author":"Malla","year":"2024","journal-title":"Mol. Therap.\u202f: J. American Soc. Gene Therap."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0465","series-title":"Cancer Research Conference","article-title":"mRNA expression and delivery efficacy of lipid nanoparticles in the cells breast tumor microenvironment: In vitro and in vivo evaluation","author":"Tiwari","year":"2022"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast Cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mole. Therap.\u202f: J. American Soci. Gene Therap."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0475","first-page":"e2201895","article-title":"Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy","volume":"9","author":"Su","year":"2022","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0480","first-page":"e2201496","article-title":"A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models","volume":"9","author":"Jing","year":"2022","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119649","article-title":"Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses","volume":"230","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0490","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13058-015-0552-9","article-title":"Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles","volume":"17","author":"Campbell","year":"2015","journal-title":"Breast Cancer Res. : BCR"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0495","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0500","article-title":"Lipidation approaches potentiate adjuvant-pulsed immune surveillance: a design rationale for Cancer Nanovaccine","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0505","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.3390\/ijms231710068","article-title":"Lipid-based nanoparticles as a pivotal delivery approach in triple negative breast Cancer (TNBC) therapy","volume":"23","author":"Chaudhuri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109254","article-title":"Combination of a cationic complexes loaded with mRNA and \u03b1-galactose ceramide enhances antitumor immunity and affects the tumor immune microenvironment","volume":"113","author":"Guo","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2019.04.019","article-title":"MPL nano-liposomal vaccine containing P5 HER2\/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer","volume":"303","author":"Zamani","year":"2019","journal-title":"J. Control. Rel. : Off. J. Controll. Releas. Soc."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0520","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2020.01.010","article-title":"Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer","volume":"129","author":"Zamani","year":"2020","journal-title":"Eur.J. Cancer (Oxford England : 1990)"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3095","article-title":"Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: a novel vaccine for breast cancer","volume":"37","author":"Mohammadian Haftcheshmeh","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0530","first-page":"665","article-title":"P435 HER2\/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer","volume":"47","author":"Farzad","year":"2019","journal-title":"Artific. Cells, Nanomed., Biotechnol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243550","article-title":"Preparation of nanoliposomes containing HER2\/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer","volume":"15","author":"Naghibi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108148","article-title":"Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy","volume":"101","author":"Yu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0545","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imlet.2016.05.016","article-title":"Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model","volume":"176","author":"Alipour Talesh","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213566","article-title":"Transdermal delivery of brucine-encapsulated liposomes significantly enhances anti-tumor outcomes in treating triple-negative breast cancer","volume":"153","author":"Wu","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0555","article-title":"Injectable, tough alginate cryogels as cancer vaccines","volume":"7","author":"Shih","year":"2018","journal-title":"Adva. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0560","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1039\/D3TB00170A","article-title":"Injectable zwitterionic cryogels for accurate and sustained chemoimmunotherapy","volume":"11","author":"Jing","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0565","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/adhm.201400460","article-title":"CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines","volume":"4","author":"Hartmann","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0570","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.ijbiomac.2022.11.045","article-title":"Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy","volume":"223","author":"Chen","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0575","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/acs.biomac.3c01426","article-title":"Injectable alginate complex hydrogel loaded with dual-drug Nanovectors offers effective Photochemotherapy against triple-negative breast Cancer","volume":"25","author":"Lee","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.797094","article-title":"RNA hydrogel combined with MnO2 nanoparticles as a Nano-vaccine to treat triple negative breast Cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0585","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0590","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/mt.2013.52","article-title":"The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine","volume":"21","author":"Pavelko","year":"2013","journal-title":"Mol. Therap. : J. American Soc. Gene Therap."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0595","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13046-022-02501-3","article-title":"Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy","volume":"41","author":"Jugniot","year":"2022","journal-title":"J. Experiment. & Clin. Cancer Res. : CR"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2022.03.019","article-title":"Breast cancer survivors\u2019 typhoid vaccine responses: chemotherapy, obesity, and fitness make a difference","volume":"103","author":"Kiecolt-Glaser","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast Cancer: a phase 1 nonrandomized clinical trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-022-06562-y","article-title":"The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers","volume":"194","author":"Anderson","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0615","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00262-020-02503-0","article-title":"The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients","volume":"69","author":"Rosenbaum","year":"2020","journal-title":"Cancer Immunol., Immunotherap. : CII"},{"key":"10.1016\/j.jconrel.2024.05.020_bb0620","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1111\/cas.14510","article-title":"Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer","volume":"111","author":"Toh","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0625","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/CJI.0000000000000175","article-title":"Immunologic response elicited in breast Cancer patients receiving a NeuGcGM3-based vaccine as adjuvant therapy","volume":"40","author":"Valdes-Zayas","year":"2017","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2024.05.020_bb0630","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/bcr3685","article-title":"Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients","volume":"16","author":"Takahashi","year":"2014","journal-title":"Breast Cancer Res. : BCR"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924003055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924003055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T03:11:18Z","timestamp":1740193878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924003055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":126,"alternative-id":["S0168365924003055"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}